Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłoński J
Department of Immunopathology, Medical Academy of Białystok, Poland.
Arch Immunol Ther Exp (Warsz). 2001;49(1):63-9.
Simultaneous evaluation of cytokines and their soluble receptor production and the serum levels can be helpful in understanding the local and systemic immune response of a tumor-bearing host. In the present study we examined serum levels of TNF-alpha, IL-6 and their soluble receptors: sTNFRp55, sTNFRp75 and sIL-6R confronted with their production by the polymorphonuclear neutrophils (PMN) from cancer patients. Examinations were carried out in patients with adenocarcinoma breast cancer and squamous cell carcinoma of the oral cavity and related to the clinical course and to different phases of therapy. Secretion of IL-6, sTNFRp55 and sTNFRp75 by PMN appeared to be dependent on tumor type, clinical progression of disease as well as on therapy, suggesting a significant role of these cells at different phases of the immune response to cancer associated with these mediators. Changes in values of TNF-alpha, IL-6 and their soluble receptors in sera of both cancer groups, dependent on tumor type, clinical progression and cancer therapy, could have a diagnostic and prognostic role in cancer disease.
同时评估细胞因子及其可溶性受体的产生情况以及血清水平，有助于了解荷瘤宿主的局部和全身免疫反应。在本研究中，我们检测了癌症患者多形核中性粒细胞（PMN）产生的肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）及其可溶性受体：可溶性肿瘤坏死因子受体p55（sTNFRp55）、可溶性肿瘤坏死因子受体p75（sTNFRp75）和可溶性白细胞介素-6受体（sIL-6R），并同时检测了其血清水平。对乳腺癌腺癌患者和口腔鳞状细胞癌患者进行了检测，并将结果与临床病程及不同治疗阶段相关联。PMN分泌IL-6、sTNFRp55和sTNFRp75似乎取决于肿瘤类型、疾病的临床进展以及治疗情况，这表明这些细胞在与这些介质相关的癌症免疫反应的不同阶段发挥着重要作用。两个癌症组血清中TNF-α、IL-6及其可溶性受体的值的变化，取决于肿瘤类型、临床进展和癌症治疗情况，可能在癌症疾病中具有诊断和预后作用。
